Sugi Predict

Sugi Predict / Compounds / SCHEMBL7188511

SCHEMBL7188511

SCHEMBL7188511

COC(C)Oc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)cc1.[LiH]

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ PPARG P37231 2/20 0.34
▸ PPARA Q07869 2/20 0.34
▸ MAOB P27338 4/20 0.33
▸ GAA P10253 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ AKR1C4 P17516 1/20 0.32
▸ AKR1C3 P42330 1/20 0.32
▸ AKR1C2 P52895 1/20 0.32
▸ AKR1C1 Q04828 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ MAOA P21397 1/20 0.32
▸ EPHX2 P34913 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ MMP1 P03956 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181619 0.90 POLB (0.39) PPARGPPARAGAALMNAMEN1
SCHEMBL7181435 0.88 FFAR1 (0.35) PPARGPPARAMAOBGAAKMT2A
SCHEMBL7180687 0.85 MAOB (0.45) SMN1; SMN2MAOBGAALMNAMAPT
SCHEMBL7177823 0.85 ACACB (0.37) PPARGPPARAMAOBGAALMNA
SCHEMBL7182795 0.83 MRGPRX4 (0.34) SMN1; SMN2MAOBGAALMNAMAPT
SCHEMBL7177789 0.82 AKR1C3 (0.33) SMN1; SMN2PPARGMAOBGAALMNA
SCHEMBL7188852 0.82 ALDH1A1 (0.35) SMN1; SMN2PPARGPPARAGAAMAPT
SCHEMBL7188651 0.82 PPARG (0.33) SMN1; SMN2PPARGPPARAGAAMEN1
SCHEMBL7182426 0.81 PDK2 (0.39) MAOBMAPTMEN1KMT2AMAOA
Lithium SCHEMBL7181101 0.81 TDP1 (0.33) SMN1; SMN2MAOBGAALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885PPARG 2956/4885PPARA 3039/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885PPARG 2776/4885PPARA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.